Background Androgen deprivation therapy is a first-line treatment for disseminated prostate
cancer (PCa). However, virtually all tumors become resistant and recur as castration-
resistant PCa, which has no durable cure. One major hurdle in the development of more
effective therapies is the lack of preclinical models that adequately recapitulate the
heterogeneity of PCa, significantly hindering the ability to accurately predict therapeutic
response. Objective To leverage the ex vivo culture method termed patient-derived explant …